Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of “Buy” by Analysts

Altimmune, Inc. (NASDAQ:ALT) has earned a consensus recommendation of “Buy” from the eight research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $20.83.

Several brokerages have commented on ALT. UBS Group began coverage on shares of Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price objective for the company. Stifel Nicolaus assumed coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Wednesday, January 22nd.

Altimmune Price Performance

ALT opened at $6.64 on Friday. Altimmune has a one year low of $5.28 and a one year high of $14.84. The business has a 50 day simple moving average of $7.78 and a two-hundred day simple moving average of $7.18. The firm has a market capitalization of $472.24 million, a price-to-earnings ratio of -4.28 and a beta of 0.22.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter last year, the company posted ($0.39) earnings per share. As a group, sell-side analysts expect that Altimmune will post -1.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in shares of Altimmune by 4.7% during the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after buying an additional 74,194 shares during the period. Bellevue Group AG increased its position in Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after purchasing an additional 263,660 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after purchasing an additional 335,444 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Altimmune by 74.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock worth $1,331,000 after purchasing an additional 92,498 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after buying an additional 4,772 shares during the period. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.